Addex seeks partner for dyskinesia drug after positive Phase II
This article was originally published in Scrip
Executive Summary
Swiss biotech firm Addex Therapeutics has reported positive top-line Phase IIa data for dipraglurant (ADX48621), its mGluR5 negative allosteric modulator for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID), and said it intends to seek a partner to progress dipraglurant to the market as rapidly as possible.